Developer docs
API playgroundTry for free, no card

Search company profiles

ExAdEx-Innov

Full company profile

uuid000kekx

Namestring
ExAdEx-Innov
Legal namestring
ExAdEx-Innov
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNice, France
HQ citystring
Nice
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ex vivo tissue models, preclinical drug testing, dermo-cosmetic research, adipose tissue models, biotech R&D services
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Preclinical Biotechnology Research Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1R&D Services and Testing
TypeProfessional Services
Description

Provides assay and analytical services to pharmaceutical, cosmetic, and nutraceutical companies. Offers multi-parametric testing across molecular, functional, and metabolic activity assays using their ex vivo tissue models. Services include custom study design, tissue sourcing, and comprehensive analysis packages.

exadex-innov.com
2Technology Licensing
TypeLicensing Royalties
Description

Licenses proprietary ExAdEx technology and patented tissue models to partners for specific applications. Includes license agreements for technology platforms (e.g., hMADS cells from CNRS Innovation).

exadex-innov.com
3Collaborative Research/Co-development
TypeProfessional Services
Description

Joint development projects with cosmetic ingredient suppliers and pharmaceutical companies for specific product validation and claim substantiation. Includes partnership agreements with Exsymol Monaco and Mibelle Biochemistry.

exadex-innov.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1ExAdEx Longevity Lab
Description

Hybrid in-silico/ex vivo platform for tissue and metabolic longevity research integrating 24 aging-related endpoints

exadex-innov.com
+3 more records
Core offering1 text field

ExAdEx-Innov develops and commercializes patented ex vivo human adipose (fat) tissue models derived from donor tissue for pharmaceutical, dermo-cosmetic, nutraceutical, and aesthetic medicine R&D. The models preserve native 3D vascularization, lymphatic networks, and extracellular matrix for up to 8 weeks in culture, enabling human-relevant preclinical testing, drug development for obesity and metabolic diseases, and claim substantiation for cosmetic ingredients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 3D models viable for up to 8 weeks in culture
+2 more records
Product overview1 text field

ExAdEx-Innov offers a portfolio centered on its patented ExAdEx technology platform for ex vivo human tissue modeling. The core offering comprises the ExAdEx Platform providing 3D donor-derived human adipose tissue models preserved with native vascular/lymphatic networks and extracellular matrix. Key products include ObAdEx (a biotherapy in preclinical development for obesity treatment) and the ExAdEx Longevity Lab (a hybrid in-silico/ex vivo platform for tissue longevity research with 24 aging endpoints). The platform serves pharmaceuticals (drug development for obesity and metabolic diseases) and dermo-cosmetics (ingredient testing and claims validation) through specialized sub-products including 3D Vascular Models, 3D Tissue Matrix Models, and 3D Fat Tissue Models, supported by assay services for vascular/lymphatic analysis, fibrosis/inflammation testing, and slimming/CELLULITE evaluation, plus 3D/4D imaging services.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

Partnership for preclinical validation of RES-010 antisense oligonucleotide for obesity therapy. Provided human 3D adipose tissue models for miR-22 inhibition studies demonstrating mitochondrial activation and browning effects. Resalis presented results at Obesity Week 2025.

2Business France Nordics and Bpifrance
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2025-10-20
Description

Participated in Nordic Life Science Mission organized by Business France Nordics and Bpifrance. Included visits to AstraZeneca BioVentureHub, pitching to Novo Nordisk, Lundbeck, LEO Pharma, and Danish biotech ecosystem engagement.

exadex-innov.com
3Mibelle Group Biochemistry
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

Contributed to development of VividEYE™ product - an apple mint extract for eye care. Provided 3D vascularized donor-derived ex vivo models and advanced 3D/4D imaging analysis to support claims for dark circles and under-eye puffiness. Demonstrates cross-industry innovation capability.

exadex-innov.com
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2024-05-21
Description

Presentation at 3R LÄND Conference 2024 in Tübingen showcasing organoid models as non-animal methods (NAM) for human adipose tissue research. Engagement with academic labs, clinicians, industry and regulatory agencies committed to reduce animal experimentation.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-02-29
Description

License agreement with CNRS Innovation for hMADS (Human Multipotent Adipose-Derived Stem) 2D stem cell model to complement the proprietary 3D ExAdEx platform. Integrates standardized 2D screening capabilities with 3D tissue models for comprehensive research from screening to mechanistic studies.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-11-15
Description

Collaboration for innovative cosmetic research. Exsymol, a leader in active ingredients for cosmetics and nutrition for over 45 years (known for Silanols technology), partnered to test CAFEISILANE ingredient on ExAdEx fibro-inflammatory tissue models. Significant milestone demonstrating platform capability for human adipose tissue research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership with iBV at Université Côte d'Azur. Source of foundational technology and ongoing R&D collaboration. Lab team led by Christian Dani (Team Leader of Stem Cells and Differentiation). Labeled Labex Signalife by French National Research Agency.

8Institute of Molecular and Cellular Pharmacology (IPMC)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration on ObFAT-3D project with IPMC team directed by Dr Bernard Mari and Dr Georges Vassaux. Joint research on 3D ex vivo human tissues to mimic obese adipose tissue, co-funded by IdEx Innovation Program France 2030 and ANRT CIFRE PhD program.

exadex-innov.com
9Centre Hospitalier Universitaire (CHU) de Nice
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with Digestive Surgery Department directed by Professor Antonio Iannelli. Provides clinical expertise and tissue sourcing. Research on adipose tissue and obesity, including ECO 2024 poster presentation on vascularized organoids.

exadex-innov.com
10PRISM Imaging Facility (Institut de Biologie Valrose)
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration for 4D imaging analysis techniques. PRISM facility provides advanced imaging expertise for quantitative evaluation of vascular and lymphatic networks in 3D tissue models, including novel volume reconstruction techniques.

exadex-innov.com
11La French Tech Côte d'Azur
Strategic tierSupportingTypeGTM or Marketing Partner
Description

Membership in French Tech mission and regional La French Tech Côte d'Azur association gathering entrepreneurs, startups and investors to boost development of French innovative and deeptech companies.

exadex-innov.com
12Centre for Cardiovascular and Nutrition Research (C2VN), Marseille
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborative research on nanofat in regenerative medicine published in Facial Plastic Surgery & Aesthetic Medicine. Comprehensive review and consensus recommendations from expert opinions on nanofat applications.

exadex-innov.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership including IdEx Innovation Program France 2030 funding. Multiple collaborative projects including ObFAT-3D project co-funded by university and Association Nationale de la Recherche et de la Technologie (ANRT).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss 3D microtissue company offering organotypic tissue models for drug discovery and safety testing. Comparable as a provider of human-derived 3D tissue models to pharma and cosmetics companies for preclinical evaluation and claim substantiation.

2CN Bio
TypeDirect peer
Description

UK organ-on-chip company developing single- and multi-organ microphysiological systems for drug development. Direct peer in the organ-on-chip / human tissue model category, with overlap in pharma preclinical customers and similar NAM regulatory positioning.

TypeBroad incumbent
Description

L'Oréal-owned pioneer of reconstructed human skin models for in vitro cosmetic and pharmaceutical testing. A broad incumbent in the same tissue-based testing category for cosmetics R&D, though specializing in skin (epidermis/dermis) rather than adipose tissue and serving as both potential competitor and ecosystem leader.

TypeDirect peer
Description

Dutch organ-on-chip company providing 3D microfluidic tissue models for pharmaceutical drug discovery and toxicology. Closely comparable in offering human-relevant in vitro tissue platforms to pharma and cosmetics R&D customers, though MIMETAS is more general-purpose and significantly larger.

TypeDirect peer
Description

US company building multi-organ 'human-on-a-chip' systems for preclinical drug testing without animal models. Comparable as a human-relevant NAM provider targeting pharmaceutical drug development with similar translational value proposition.

TypeDirect peer
Description

US-based organ-on-chip platform using its proprietary chip technology to model human organ function for pharma R&D. Directly comparable as a human-relevant preclinical tissue model provider serving similar pharmaceutical customers, with a broader organ portfolio than ExAdEx-Innov.

TypeDirect peer
Description

German multi-organ-on-chip company developing microphysiological systems for pharma, cosmetics, and chemical industry testing. Direct peer in the human-tissue-chip/NAM space with overlapping European customer base in pharma and dermo-cosmetics.

TypeRegional player
Description

French company supplying human biological tissues, primary cells, and in vitro testing services to pharma, cosmetics, and chemical industries. Regional peer with overlapping service offering (human tissue-based testing for R&D) and a similar French/European customer base, though broader in tissue scope.

9Straticell
TypeDirect peer
Description

Belgian in vitro testing company offering 3D skin and mucosal tissue models for cosmetic, pharmaceutical, and chemical industry R&D. Comparable as a tissue-model-based testing services provider with similar cosmetics/derma-cosmetic customer use cases.

TypeDirect peer
Description

US-based provider of 3D reconstructed human tissue models (skin, ocular, airway, etc.) used by cosmetics, pharmaceutical, and chemical companies for safety and efficacy testing. Closely comparable in product category (3D human tissue models for cosmetics/pharma R&D) though focused on different tissue types.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ExAdEx-Innov

Preclinical Biotechnology Research Servicesexadex-innov.com

ExAdEx-Innov firmographics

Firmographics
Name
ExAdEx-Innov
Legal name
ExAdEx-Innov
Website
https://exadex-innov.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

ExAdEx-Innov industry classification

Industry
Product category
Preclinical Biotechnology Research Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Ex vivo tissue models
  • Preclinical drug testing
  • Dermo-cosmetic research
  • Adipose tissue models
  • Biotech R&D services

Where ExAdEx-Innov is headquartered

Location

Headquarters

HQ city
Nice
HQ country
France
HQ region
Europe

Offices2 records

Markets served

ExAdEx-Innov business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. R&D Services and Testing: Provides assay and analytical services to pharmaceutical, cosmetic, and nutraceutical companies. Offers multi-parametric testing across molecular, functional, and metabolic activity assays using their ex vivo tissue models. Services include custom study design, tissue sourcing, and comprehensive analysis packages.
  2. Technology Licensing: Licenses proprietary ExAdEx technology and patented tissue models to partners for specific applications. Includes license agreements for technology platforms (e.g., hMADS cells from CNRS Innovation).
  3. Collaborative Research/Co-development: Joint development projects with cosmetic ingredient suppliers and pharmaceutical companies for specific product validation and claim substantiation. Includes partnership agreements with Exsymol Monaco and Mibelle Biochemistry.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels5 records

ExAdEx-Innov product offering

Product offering

Core offering

ExAdEx-Innov develops and commercializes patented ex vivo human adipose (fat) tissue models derived from donor tissue for pharmaceutical, dermo-cosmetic, nutraceutical, and aesthetic medicine R&D. The models preserve native 3D vascularization, lymphatic networks, and extracellular matrix for up to 8 weeks in culture, enabling human-relevant preclinical testing, drug development for obesity and metabolic diseases, and claim substantiation for cosmetic ingredients.

Product overview

ExAdEx-Innov offers a portfolio centered on its patented ExAdEx technology platform for ex vivo human tissue modeling. The core offering comprises the ExAdEx Platform providing 3D donor-derived human adipose tissue models preserved with native vascular/lymphatic networks and extracellular matrix. Key products include ObAdEx (a biotherapy in preclinical development for obesity treatment) and the ExAdEx Longevity Lab (a hybrid in-silico/ex vivo platform for tissue longevity research with 24 aging endpoints). The platform serves pharmaceuticals (drug development for obesity and metabolic diseases) and dermo-cosmetics (ingredient testing and claims validation) through specialized sub-products including 3D Vascular Models, 3D Tissue Matrix Models, and 3D Fat Tissue Models, supported by assay services for vascular/lymphatic analysis, fibrosis/inflammation testing, and slimming/CELLULITE evaluation, plus 3D/4D imaging services.

Differentiator

Problem solved

Functional benefit

Brands

  • ExAdEx Longevity Lab: Hybrid in-silico/ex vivo platform for tissue and metabolic longevity research integrating 24 aging-related endpoints
  • ExAdEx Platform
  • ObAdEx
  • ObFAT-3D

Quantifiable outcome

  • 3D models viable for up to 8 weeks in culture
  • +2 more outcomes

Companies that use ExAdEx-Innov

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

ExAdEx-Innov technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ExAdEx-Innov partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered major, supporting and core.

  • Resalis TherapeuticsmajorStrategic or Co-development Partner · 29 October 2025Partnership for preclinical validation of RES-010 antisense oligonucleotide for obesity therapy. Provided human 3D adipose tissue models for miR-22 inhibition studies demonstrating mitochondrial activation and browning effects. Resalis presented results at Obesity Week 2025.
  • Business France Nordics and BpifrancesupportingGTM or Marketing Partner · 20 October 2025Participated in Nordic Life Science Mission organized by Business France Nordics and Bpifrance. Included visits to AstraZeneca BioVentureHub, pitching to Novo Nordisk, Lundbeck, LEO Pharma, and Danish biotech ecosystem engagement.
  • Mibelle Group BiochemistrymajorStrategic or Co-development Partner · 19 November 2024Contributed to development of VividEYE™ product - an apple mint extract for eye care. Provided 3D vascularized donor-derived ex vivo models and advanced 3D/4D imaging analysis to support claims for dark circles and under-eye puffiness. Demonstrates cross-industry innovation capability.
  • 3R-Center Tübingen for In vitro Models and Alternatives to Animal TestingsupportingGTM or Marketing Partner · 21 May 2024Presentation at 3R LÄND Conference 2024 in Tübingen showcasing organoid models as non-animal methods (NAM) for human adipose tissue research. Engagement with academic labs, clinicians, industry and regulatory agencies committed to reduce animal experimentation.
  • CNRS InnovationcoreTechnology or Integration · 29 February 2024License agreement with CNRS Innovation for hMADS (Human Multipotent Adipose-Derived Stem) 2D stem cell model to complement the proprietary 3D ExAdEx platform. Integrates standardized 2D screening capabilities with 3D tissue models for comprehensive research from screening to mechanistic studies.
  • Exsymol MonacomajorStrategic or Co-development Partner · 15 November 2023Collaboration for innovative cosmetic research. Exsymol, a leader in active ingredients for cosmetics and nutrition for over 45 years (known for Silanols technology), partnered to test CAFEISILANE ingredient on ExAdEx fibro-inflammatory tissue models. Significant milestone demonstrating platform capability for human adipose tissue research.
  • Institut de Biologie Valrose (iBV)coreStrategic or Co-development PartnerAcademic research partnership with iBV at Université Côte d'Azur. Source of foundational technology and ongoing R&D collaboration. Lab team led by Christian Dani (Team Leader of Stem Cells and Differentiation). Labeled Labex Signalife by French National Research Agency.
  • Institute of Molecular and Cellular Pharmacology (IPMC)majorStrategic or Co-development PartnerCollaboration on ObFAT-3D project with IPMC team directed by Dr Bernard Mari and Dr Georges Vassaux. Joint research on 3D ex vivo human tissues to mimic obese adipose tissue, co-funded by IdEx Innovation Program France 2030 and ANRT CIFRE PhD program.
  • Centre Hospitalier Universitaire (CHU) de NicemajorStrategic or Co-development PartnerCollaboration with Digestive Surgery Department directed by Professor Antonio Iannelli. Provides clinical expertise and tissue sourcing. Research on adipose tissue and obesity, including ECO 2024 poster presentation on vascularized organoids.
  • PRISM Imaging Facility (Institut de Biologie Valrose)coreTechnology or IntegrationCollaboration for 4D imaging analysis techniques. PRISM facility provides advanced imaging expertise for quantitative evaluation of vascular and lymphatic networks in 3D tissue models, including novel volume reconstruction techniques.
  • La French Tech Côte d'AzursupportingGTM or Marketing PartnerMembership in French Tech mission and regional La French Tech Côte d'Azur association gathering entrepreneurs, startups and investors to boost development of French innovative and deeptech companies.
  • Centre for Cardiovascular and Nutrition Research (C2VN), MarseillemajorStrategic or Co-development PartnerCollaborative research on nanofat in regenerative medicine published in Facial Plastic Surgery & Aesthetic Medicine. Comprehensive review and consensus recommendations from expert opinions on nanofat applications.
  • Université Côte d'AzurcoreStrategic or Co-development PartnerAcademic research partnership including IdEx Innovation Program France 2030 funding. Multiple collaborative projects including ObFAT-3D project co-funded by university and Association Nationale de la Recherche et de la Technologie (ANRT).

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

ExAdEx-Innov competitors and assessment

Company assessment

Direct peers

  • InSphero: Swiss 3D microtissue company offering organotypic tissue models for drug discovery and safety testing. Comparable as a provider of human-derived 3D tissue models to pharma and cosmetics companies for preclinical evaluation and claim substantiation.
  • CN Bio: UK organ-on-chip company developing single- and multi-organ microphysiological systems for drug development. Direct peer in the organ-on-chip / human tissue model category, with overlap in pharma preclinical customers and similar NAM regulatory positioning.
  • MIMETAS: Dutch organ-on-chip company providing 3D microfluidic tissue models for pharmaceutical drug discovery and toxicology. Closely comparable in offering human-relevant in vitro tissue platforms to pharma and cosmetics R&D customers, though MIMETAS is more general-purpose and significantly larger.
  • Hesperos: US company building multi-organ 'human-on-a-chip' systems for preclinical drug testing without animal models. Comparable as a human-relevant NAM provider targeting pharmaceutical drug development with similar translational value proposition.
  • Emulate: US-based organ-on-chip platform using its proprietary chip technology to model human organ function for pharma R&D. Directly comparable as a human-relevant preclinical tissue model provider serving similar pharmaceutical customers, with a broader organ portfolio than ExAdEx-Innov.
  • TissUse: German multi-organ-on-chip company developing microphysiological systems for pharma, cosmetics, and chemical industry testing. Direct peer in the human-tissue-chip/NAM space with overlapping European customer base in pharma and dermo-cosmetics.
  • Straticell: Belgian in vitro testing company offering 3D skin and mucosal tissue models for cosmetic, pharmaceutical, and chemical industry R&D. Comparable as a tissue-model-based testing services provider with similar cosmetics/derma-cosmetic customer use cases.
  • MatTek: US-based provider of 3D reconstructed human tissue models (skin, ocular, airway, etc.) used by cosmetics, pharmaceutical, and chemical companies for safety and efficacy testing. Closely comparable in product category (3D human tissue models for cosmetics/pharma R&D) though focused on different tissue types.

Broad incumbents

  • EpiSkin (L'Oréal): L'Oréal-owned pioneer of reconstructed human skin models for in vitro cosmetic and pharmaceutical testing. A broad incumbent in the same tissue-based testing category for cosmetics R&D, though specializing in skin (epidermis/dermis) rather than adipose tissue and serving as both potential competitor and ecosystem leader.

Regional players

  • Biopredic International: French company supplying human biological tissues, primary cells, and in vitro testing services to pharma, cosmetics, and chemical industries. Regional peer with overlapping service offering (human tissue-based testing for R&D) and a similar French/European customer base, though broader in tissue scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ExAdEx-Innov social profiles

Digital presence

ExAdEx-Innov financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ExAdEx-Innov leadership team

Management profile

Number of profiles

Profiles9 records

ExAdEx-Innov funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ExAdEx-Innov M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExAdEx-Innov

What does ExAdEx-Innov do?

ExAdEx-Innov develops and commercializes patented ex vivo human adipose (fat) tissue models derived from donor tissue for pharmaceutical, dermo-cosmetic, nutraceutical, and aesthetic medicine R&D. The models preserve native 3D vascularization, lymphatic networks, and extracellular matrix for up to 8 weeks in culture, enabling human-relevant preclinical testing, drug development for obesity and metabolic diseases, and claim substantiation for cosmetic ingredients.

Is ExAdEx-Innov a public or private company?

ExAdEx-Innov is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ExAdEx-Innov founded?

ExAdEx-Innov was founded in 2022. It employs 1 to 10 people.

Where is ExAdEx-Innov based?

ExAdEx-Innov is headquartered in Nice, France, in the Europe region.

How does ExAdEx-Innov make money?

Three revenue lines are on record. R&D Services and Testing is the primary driver. The others are technology Licensing and collaborative Research/Co-development.

Who are ExAdEx-Innov's main competitors?

Direct peers on record are InSphero, CN Bio, MIMETAS, Hesperos, Emulate, TissUse, Straticell and MatTek. EpiSkin (L'Oréal) is listed as a broad incumbent. Biopredic International is listed as a regional player.

Does ExAdEx-Innov have an API?

No public API is recorded for ExAdEx-Innov.

What industry is ExAdEx-Innov in?

ExAdEx-Innov's product category is Preclinical Biotechnology Research Services. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales